Centre to Impact AMR

Superbugs are becoming more prevalent and more extreme. How science rethinks its response will determine the outcome of one of the great health threats of the 21st century.

We can win the fight, but it requires a paradigm shift in thinking. The days of relying on  “silver bullet” drugs are over.

Our Centre’s approach is multifaceted and multidisciplinary.

Our teams are tracking and mapping superbugs to assist in making informed intervention decisions, developing unique antimicrobial surfaces to curb their spread, exploring new treatments to complement or replace old ones, and working to prolong the life of existing antibiotics.

We believe it is possible to turn the tide, and again take control.

We also are determined to help all Australians change the way they think about and use antibiotics and other antimicrobials, so that we are all part of the solution, not the problem.

Our aim is to drive the transformation of the global approach to the resistance of superbugs by leading the evolution of science, policy, behaviours, environments and skills development.

There will be challenges, but we are up for the fight.

News & Updates

View more articles

Partnerships and Industry

The Monash Centre to Impact Antimicrobial Resistance works with industry, government and other organisations, through funded collaborative research and provision of contract research services.

Our research partnerships draw on the Centre’s interdisciplinary expertise network of its 25 world-leading research leaders and the research capability provided by the Centre’s Antimicrobial Resistance R&D Facility. This enables our partners to work with us at all stages of the R&D pipeline, from understanding the fundamental biology of Antimicrobial resistance to engineering new detection methods and changing public thinking about AMR.

Beating the superbugs - A Different Lens production

Meet Monash researchers and sepsis survivor Mandy McCracken, who talk about the impact of superbug infections.

Monash researchers are responding to the global call for new solutions to drug-resistant infections. From drug discovery, rethinking current therapeutics to investigating the potential of Phage Therapy.

Mandy McCracken was hospitalised in 2013  with a Group A Streptococcal infection that led to sepsis and ultimately the loss of all her limbs.

Click the LINK Below


Keep up-to-date with global and local antimicrobial resistance issues via our social media feeds